Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Susanna BianzanoAnita M HennigeMatias NordabyLeona Plum-MörschelBarbara PeilTim HeisePublished in: Diabetes, obesity & metabolism (2022)
BI 187004 was generally well tolerated in patients with T2DM. Despite complete 11β-HSD1 inhibition, no clinically relevant effects were observed with BI 187004. This article is protected by copyright. All rights reserved.